Sitemap Contact Worldwide Synthon company websites About Us Biopharmaceuticals Generics Products News Careers Synthon is a company committed to delivering affordable medicines through innovative science. Good health and a happy life is something we all rightly aspire to. We believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all an ability to innovate. Synthon Biopharmaceuticals Distinctive in Generics Auto-injector Device LATEST NEWS 5/18/2016 Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients 9/28/2015 Synthon Reports Promising Initial Results from Phase I Trial with anti-HER2 ADC SYD985 8/3/2015 Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis Go to News and Media Science Pipeline Biopharmaceuticals Pipeline Generics Scientific platforms Partners BD Biopharmaceuticals BD Generics Products Scientific platforms Strategy Media Press releases Contact information Job Seekers Job openings Open applications Follow us facebook twitter linkedin RSS Feed Terms of use

United States Sitemap Contact Worldwide Synthon company websites About us Research Products News Careers Synthon is a company committed to delivering affordable medicines through innovative science. Good health and a happy life is something we all rightly aspire to. We believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all an ability to innovate. CORPORATE PRESS RELEASES 5/18/2016 Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients 9/28/2015 Synthon Reports Promising Initial Results from Phase I Trial with anti-HER2 ADC SYD985 8/3/2015 Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis Go to Corporate Synthon website Science Biopharmaceutical R&D Generic R&D Partners Products Strategy Media Contact information Job seekers Job openings Open applications Follow us facebook twitter linkedin RSS Feed Terms of use